Furor rages over FDA approval of controversial Alzheimer`s drug
(Washington Post Health & Science)

For days, critics have blasted the approval in opinion columns and tweets, saying there is insufficient evidence of efficacy. Supporters have expressed confidence the drug, Aduhelm, will help patients stay in the earliest stages of the disease longer.